Key Highlights
- Net loss was USD 7.96 million, compared with USD 9.35 million a year earlier.
- Research and development expenses were USD 5.7 million, compared with USD 7.0 million.
- Cash, cash equivalents and investments totaled USD 80.2 million at September 30.
- The accumulated Deficit was USD 267.1 million.
AN2 Therapeutics, Inc. (NASDAQ:ANTX) reported a third quarter 2026 net loss of USD 7.96 million, compared with USD 9.35 million in the third quarter of 2025. Reported EPS was negative USD 0.17, compared with an estimate of negative USD 0.20. The company reported no revenue.
Total operating expenses were USD 8.67 million, compared with USD 10.04 million. Interest income was USD 0.7 million in both periods.
Expense Detail
Research and development expenses were USD 5.7 million, compared with USD 7.0 million, a decrease of USD 1.3 million. Preclinical and research study expenses decreased USD 1.0 million as certain compounds completed the preclinical research stage. Other miscellaneous expenses decreased USD 0.5 million on updated estimates of provisional indirect cost rates under the NIAID contract in 2025. Clinical trial expenses decreased USD 0.3 million due to completion of the Chagas Phase 1 study, partly offset by start-up costs for Phase 2 trials. Personnel-related expenses increased USD 0.4 million, primarily on stock-based compensation, and CMC expenses increased USD 0.1 million.
Reimbursement of operating expenses recognized under funding arrangements was USD 0.7 million, compared with USD 0.3 million. General and administrative expenses were USD 2.9 million, compared with USD 3.0 million.
For the nine months, Research and Development expenses were USD 18.5 million compared with USD 17.9 million, general and administrative expenses were USD 9.6 million compared with USD 10.9 million, and the net loss was USD 26.2 million compared with USD 26.5 million.
Liquidity
The company held cash, cash equivalents, short-term and Long-Term Investments of USD 80.2 million at September 30, 2026. It states that, based on its current plan, available cash is sufficient to fund operations for at least 12 months following the date of the filing. In the nine months, it sold 1,692,768 shares under its ATM offerings for net proceeds of USD 8.0 million, and in March 2026 it generated approximately USD 37.2 million from a private placement.
Pipeline Programs
Study startup activities are underway for a global Phase 2 study, EBO-PV-201, of oral epetraborole in adults with phlebotomy-dependent polycythemia vera, a condition estimated to affect approximately 155,000 people in the U.S. The company projects beginning enrollment by the end of 2026, with Part 1 data released periodically throughout 2027.
An 84-patient multicenter, randomized, double-blind, placebo-controlled study across an estimated 10 to 15 U.S. sites is scheduled to report topline results in late 2027, subject to enrollment progress.
For Chagas disease, the company announced positive results in June 2026 from two studies for AN2-502998. In the nonhuman primate study, 28 days of treatment resulted in 100% parasitic elimination at target exposures attainable in humans. A Phase 2 proof-of-concept study in adults with chronic disease is in startup. For hypophosphatasia, the company selected AN2-504661, an oral ENPP1 inhibitor, as its development candidate and plans to initiate a Phase 1 study in the second half of 2027.
Milestones to Watch
Disclosed milestones include the end-of-2026 enrollment start for the polycythemia vera study, 2027 data releases from Part 1, the late 2027 topline results from the 84-patient study and the second-half 2027 Phase 1 start for the hypophosphatasia candidate. The company's filing notes that it expects to incur substantial additional losses in future periods.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...